Mitsubishi UFJ Asset Management
NBIX icon

Mitsubishi UFJ Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8M Buy
111,484
+422
+0.4% +$62.6K 0.01% 535
2026
Q1 		$14.6M Buy
111,062
+10,840
+11% +$1.44M 0.01% 553
2025
Q4 		$14.1M Buy
100,222
+9,586
+11% +$1.39M 0.01% 553
2025
Q3 		$12.7M Sell
90,636
-752
-0.8% -$102K 0.01% 557
2025
Q2 		$11.5M Buy
91,388
+14,466
+19% +$1.66M 0.01% 559
2025
Q1 		$8.51M Hold
76,922
– – 0.01% 588
2024
Q4 		$10.6M Buy
76,922
+9,086
+13% +$1.12M 0.01% 580
2024
Q3 		$7.82M Buy
67,836
+3,438
+5% +$471K 0.01% 592
2024
Q2 		$8.87M Buy
64,398
+9,204
+17% +$1.26M 0.01% 563
2024
Q1 		$7.61M Buy
55,194
+14,015
+34% +$1.91M 0.01% 574
2023
Q4 		$5.47M Buy
41,179
+28
+0.1% +$3.22K 0.01% 590
2023
Q3 		$4.63M Buy
41,151
+85
+0.2% +$8.95K 0.01% 612
2023
Q2 		$3.87M Buy
41,066
+6,113
+17% +$597K 0.01% 638
2023
Q1 		$3.54M Buy
34,953
+4,306
+14% +$448K 0.01% 633
2022
Q4 		$3.68M Buy
30,647
+3,070
+11% +$360K 0.01% 607
2022
Q3 		$2.93M Sell
27,577
-43
-0.2% -$4.36K 0.01% 637
2022
Q2 		$2.69M Buy
27,620
+4,073
+17% +$376K 0.01% 648
2022
Q1 		$2.21M Sell
23,547
-294
-1% -$24.9K 0.01% 715
2021
Q4 		$2.11M Buy
23,841
+2,649
+13% +$244K 0.01% 745
2021
Q3 		$2.03M Buy
21,192
+355
+2% +$33.5K 0.01% 730
2021
Q2 		$2.03M Buy
20,837
+2,409
+13% +$231K 0.01% 738
2021
Q1 		$1.79M Buy
18,428
+1,368
+8% +$143K 0.01% 713
2020
Q4 		$1.64M Buy
17,060
+869
+5% +$83.9K 0.01% 692
2020
Q3 		$1.56M Buy
16,191
+2,094
+15% +$242K 0.01% 637
2020
Q2 		$1.72M Buy
14,097
+1,069
+8% +$118K 0.02% 576
2020
Q1 		$1.13M Sell
13,028
-1,293
-9% -$127K 0.02% 595
2019
Q4 		$1.57M Buy
+14,321
New +$1.5M 0.02% 597

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mitsubishi UFJ Asset Management's NBIX Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management increased its Neurocrine Biosciences (NBIX) stake by 0.38% in Q2 2026, buying an estimated $62.6K and bringing the position to 111,484 shares worth $18.8M. The position accounts for 0.01% of the portfolio, ranked #535.

Mitsubishi UFJ Asset Management first reported a position in NBIX in Q4 2019 and has held it in 27 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 111,484 shares of Neurocrine Biosciences worth $18.8M as of Q2 2026.
  • Mitsubishi UFJ Asset Management bought 422 Neurocrine Biosciences shares in Q2 2026, an estimated $62.6K.
  • Neurocrine Biosciences made up 0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #535 holding.
  • Mitsubishi UFJ Asset Management first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 27 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.